The objectives of the current Poster are: To review the different treatment response criteria in patients with pancreatic ductal adenocarcinoma To suggest the most useful imaging features to assess tumor modifications after chemotherapy To investigate the possible response criteria of the coming years.

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading neoplasms of the gastrointestinal tract and the twelfth most common cancer in the world [1]. Due to the lack of effective screening programs, by 2030 pancreatic cancer is projected to surpass breast, lung, and colorectal cancers to become the second leading cause of cancer-related death in the Western World [2]. At present, surgical resection is the only potentially curative treatment; it is possible in cases which do not show major vessels involvement and distant metastasis [3]....

RECIST CRITERIA The original Response EvaluationCriteriaIn Solid Tumors (RECIST version 1.0) were proposed on 2000 jointly by several scientific Organizations, including WHO [8]. They evaluated modifications of longest diameter of the neoplasm, and progressive disease was defined as the appearance of new lesions or a greater than 20% increase in the longest diameter. Due to the lack of assessment of lymph nodes and to the development of newer imaging technologies, the RECIST Working Group re­vised the original criteria in 2009 [9]. According to RECIST 1.1,...

Assessing treatment response of pancreatic ductal adenocarcinoma is complex; dimensions, density and tumor-vessels contact should be evaluated, but often they are not enough. For most cases it is necessary to assess also the diffusion coefficient, metabolic activity of the neoplasm and its heterogeneity. The response criteria available at the moment are incomplete; new comprehensive response criteria for pancreatic adenocarcinoma should be formulated.

1. wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics 2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913-21. 3. Hidalgo M. Pancreatic cancer. New Engl J Med. 2010;362:1605–1617. 4. Ferrone CR, Pieretti-VanmarckeR, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43–S49. 5. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Béllannée G, et al....